$135.13
6.24 (-4.41%)
Last updated: Oct 14, 2026 02:12
Fundamentals Overview
Neurocrine Biosciences Inc is near the low of its 52-week range with attractive valuation, trending downward today.
Valuation attractive
Profitability
Risk (Beta)
0.33 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
PEG 0.48 (growth vs price)
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | 19.74 |
| PEG (TTM) | 0.48 |
| P/B (TTM) | 4.59 |
| P/S (TTM) | 4.13 |
| Profitability | |
| ROE (TTM) | 21.13% |
| ROA (TTM) | 14.73% |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 20.91% |
| Gross margin (TTM) | 97.97% |
| Operating margin (TTM) | 23.56% |
| Debt to equity (TTM) | 0 |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for NBIX.
Price target data is not available for this symbol from the current data source.
Stock Grades (Institutions)
No stock grades available for this symbol.
No price targets, ratings snapshot, or grades available for this symbol.